Health&Life Co

Health&Life Co OCF/Debt

The Operating Cash Flow to Debt Ratio of Health&Life Co (1781.TWO) as of Oct 27, 2026 is 1.68 %. In the previous year, Operating Cash Flow to Debt Ratio was 17.50 % — a change of -90.43% (lower).

OCF/Debt

1.68 %

YoY

-90.43%

Last updated:

Operating Cash Flow to Debt Ratio of Health&Life Co is 2025 1.68 % . Operating Cash Flow to Debt Ratio of Health&Life Co was 2024 17.50 % . It decreases by -90.43% lower compared to the previous year.

The Health&Life Co OCF/Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

OCF/Debt
Date
OCF/Debt
Jan 1, 2018
-92.87 TWD
Jan 1, 2019
7.49 TWD
Jan 1, 2020
-15.99 TWD
Jan 1, 2021
-297.12 TWD
Jan 1, 2022
-255.94 TWD
Jan 1, 2023
441.78 TWD
Jan 1, 2024
17.50 TWD
Jan 1, 2025
1.68 TWD
The Health&Life Co OCF/Debt history
YEAROCF/DebtYoY
1.68 %-90.43%
17.50 %-96.04%
441.78 %-272.61%
-255.94 %-13.86%
-297.12 %+1,758.68%
-15.99 %-313.38%
7.49 %-108.07%
-92.87 %-121.44%
433.20 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Health&Life Co Stock analysis

What does Health&Life Co do? Health&Life Co Ltd generates revenue through the manufacturing and distribution of cardiovascular disease, in-vitro diagnostics, and respiratory care products. The company's primary products include electronic sphygmomanometers such as blood pressure monitors, nebulizers, and blood glucose monitoring systems, which measure and record systolic and diastolic blood pressure and glucose levels. These products are sold domestically in Taiwan and internationally to overseas markets. The firm targets healthcare providers, clinics, and consumers seeking home health monitoring solutions for chronic conditions like hypertension and diabetes. The company's product portfolio focuses on electronic sphygmomanometers, which are essential for daily health monitoring. By offering devices that measure blood pressure and glucose levels, Health&Life Co Ltd caters to patients managing cardiovascular and metabolic diseases. The domestic market in Taiwan serves as a key sales channel, while overseas markets provide additional growth opportunities for the firm's diagnostic and respiratory care products. Health&Life Co Ltd's business model relies on direct sales of medical devices to healthcare institutions and end-users. The firm's electronic sphygmomanometers, including blood pressure monitors and blood glucose systems, are distributed through both domestic and international channels. This approach ensures consistent revenue streams from the ongoing demand for home health monitoring equipment among patients with chronic conditions. Health&Life Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Health&Life Co stock

Operating Cash Flow to Debt Ratio of Health&Life Co is 1.68 % in 2025.

Operating Cash Flow to Debt Ratio of Health&Life Co changed from 17.50 % to 1.68 %, representing a -90.43% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow to Debt Ratio Health&Life Co since 2006 – with annual values, charts, and detailed analysis.

OCF/Debt measures what percentage of total debt can be covered by annual operating cash flow. Higher ratios indicate stronger debt repayment capacity.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Cash Flow to Debt Ratio's Health&Life Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Health&Life Co

All Key Metrics — Health&Life Co